TY - JOUR
T1 - Role of drug-coated balloons in small-vessel coronary artery disease
AU - Megaly, Michael
AU - Saad, Marwan
AU - Brilakis, Emmanouil S.
N1 - Funding Information:
Disclosure: EB: consulting/speaker honoraria from Abbott Vascular, American Heart Association (associate editor, Circulation), Boston Scientific, Cardiovascular Innovations Foundation (Board of Directors), CSI, Elsevier, GE Healthcare, InfraRedx, and Medtronic; research support from Siemens, Regeneron, and Osprey; shareholder MHI Ventures; board of trustees, Society of Cardiovascular Angiography and Interventions. The other authors have have no conflicts of interest to declare. Received: January 27, 2019 Accepted: January 31, 2019 Citation: US Cardiology Review 2019;13(1):16–20. DOI: https://doi.org/10.14520/usc.2019.4.1 Correspondence: Emmanouil S Brilakis, Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, 920 E 28th Street #300, Minneapolis, MN 55407. E: esbrilakis@gmail.com Open Access: This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly.
Publisher Copyright:
© RADCLIFFE CARDIOLOGY 2019
PY - 2019
Y1 - 2019
N2 - Percutaneous coronary intervention of small-vessel coronary artery disease (SVD) remains challenging due to difficulties with device delivery and high restenosis rate, even with the use of newer-generation drug-eluting stents. Drug-coated balloons represent an attractive emerging percutaneous coronary intervention option in patients with SVD. Potential advantages of drug-coated balloons in SVD include enhanced deliverability because of their small profile, avoidance of foreign-body implantation, and shorter duration of dual antiplatelet therapy.
AB - Percutaneous coronary intervention of small-vessel coronary artery disease (SVD) remains challenging due to difficulties with device delivery and high restenosis rate, even with the use of newer-generation drug-eluting stents. Drug-coated balloons represent an attractive emerging percutaneous coronary intervention option in patients with SVD. Potential advantages of drug-coated balloons in SVD include enhanced deliverability because of their small profile, avoidance of foreign-body implantation, and shorter duration of dual antiplatelet therapy.
KW - Coronary artery disease
KW - Drug-coated balloons
KW - Drug-eluting stents
KW - Small-vessel disease
UR - http://www.scopus.com/inward/record.url?scp=85063602907&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85063602907&partnerID=8YFLogxK
U2 - 10.14520/usc.2019.4.1
DO - 10.14520/usc.2019.4.1
M3 - Article
AN - SCOPUS:85063602907
SN - 1758-3896
VL - 13
SP - 16
EP - 20
JO - US Cardiology Review
JF - US Cardiology Review
IS - 1
ER -